Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia

被引:7
|
作者
Heffelfinger, James D. [1 ]
Voetsch, Andrew C. [1 ]
Nakamura, Glenn V. [1 ]
Sullivan, Patrick S. [2 ]
McNaghten, A. D. [1 ]
Huang, Laurence [3 ,4 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA
来源
PLOS ONE | 2009年 / 4卷 / 03期
基金
美国国家卫生研究院;
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS;
D O I
10.1371/journal.pone.0005002
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [21] Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis
    Andreasen, Philip B.
    Rezahosseini, Omid
    Moller, Dina L.
    Wareham, Neval E.
    Thomsen, Magda T.
    Houmami, Ranya
    Knudsen, Andreas D.
    Knudsen, Jenny
    Kurtzhals, Jorgen A. L.
    Rostved, Andreas A.
    Pedersen, Christian R.
    Rasmussen, Allan
    Nielsen, Susanne D.
    IMMUNITY INFLAMMATION AND DISEASE, 2022, 10 (01) : 93 - 100
  • [22] Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases
    Braga, Beatriz P.
    Prieto-Gonzalez, Sergio
    Hernandez-Rodriguez, Jose
    MEDICINA CLINICA, 2019, 152 (12): : 502 - 507
  • [23] Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors
    Proudfoot, Rebecca
    Phillips, Bob
    Wilne, Sophie
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (03) : 194 - 202
  • [24] PNEUMOCYSTIS JIROVECII PNEUMONIA IN LIVER TRANSPLANT RECIPIENTS IN AN ERA OF ROUTINE PROPHYLAXIS
    Andreasen, Philip Busch
    Rezahosseini, Omid
    Moller, Dina Leth
    Wareham, Neval Ete
    Knudsen, Jenny
    Kurtzhals, Jorgen Anders Lindholm
    Rasmussen, Allan
    Nielsen, Susanne Dam
    TRANSPLANT INTERNATIONAL, 2021, 34 : 308 - 308
  • [25] Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation
    Brakemeier, Susanne
    Pfau, Anja
    Zukunft, Bianca
    Budde, Klemens
    Nickel, Peter
    PHARMACOLOGICAL RESEARCH, 2018, 134 : 61 - 67
  • [26] Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations
    Mori, Shunsuke
    Sugimoto, Mineharu
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2015, 9 : 29 - 40
  • [27] Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors
    Arnold, Lisa M.
    Hoshina, Yoji
    Lee, Hyejung
    Colman, Howard
    Mendez, Joe
    JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (01) : 231 - 232
  • [28] Safety of trimethoprimsulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in patients taking methotrexate
    Havele, Sonia A.
    Ellis, Ariana
    Chaitoff, Alex
    Khanna, Urmi
    Parambil, Joseph
    Langford, Carol A.
    Fernandez, Anthony P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (01) : 166 - 168
  • [29] EFFECT OF PNEUMOCYSTIS JIROVECII PNEUMONIA PROPHYLAXIS ON HEMATOLOGIC TOXICITY IN PATIENTS RECEIVING CHEMORADIATION FOR PRIMARY BRAIN TUMORS
    Arnold, Lisa
    Hoshina, Yoji
    Lee, Hyejung
    Haaland, Benjamin
    Colman, Howard
    Mendez, Joe
    NEURO-ONCOLOGY, 2022, 24 : 201 - 202
  • [30] Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors
    Lisa M. Arnold
    Yoji Hoshina
    Hyejung Lee
    Howard Colman
    Joe Mendez
    Journal of Neuro-Oncology, 2024, 167 : 211 - 217